Month: May 2024

Lassila & Tikanoja plcStock exchange release6 May 2024 at 3.00 p.m. Joni Sorsanen appointed CFO of Lassila & Tikanoja plc Joni Sorsanen (M.Sc. Econ) has been appointed as Chief Financial Officer of Lassila & Tikanoja and a member of the Group Executive Board effective latest 10 July 2024. Sorsanen joins L&T from Consti plc where he serves as Chief Financial Officer. “I’m pleased to welcome Joni to our Group Executive Board to develop and lead business-driven financial operations in the Group” says Eero Hautaniemi, President and CEO of Lassila & Tikanoja. Sorsanen has extensive experience in leading and developing finance departments in listed companies. He reports to L&T’s CEO, Eero Hautaniemi. Sorsanen’s photo and résumé are available at the company website: https://www.lt.fi/en/company/group-executive-board LASSILA...

SAN FRANCISCO and WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that Michael Henderson, M.D., Chief Executive Officer and Jane Pritchett Henderson, Chief Financial Officer, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 3:40 p.m. P.T. / 6:40 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Therapeutics Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated...

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2024 financial results will be released on Monday, May 13, 2024 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website...

Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizes SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data showcasing the benefits of Aquablation therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) at both academic and commercial settings. The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas. “The data presented at AUA confirm the safety and long-term...

SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. “We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A,” said Dave Happel, CEO of Sagimet. “Having an experienced leadership team with the appropriate skillsets is critical at this key stage as we advance denifanstat into a registrational Phase...

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City. Management will be holding one-on-one meetings with investors. About Processa Pharmaceuticals, Inc. Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining its novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach, as well as...

Fingerprints today announced that the company has signed a patent license agreement with a major global company as the licensee. This represents a milestone as Fingerprints’ first-ever patent license agreement, arising from the New Business team initiative which was announced in July 2023 with the aim of developing new business and driving revenue growth. One of the focus areas for the New Business unit is the monetization of our strong portfolio of intellectual property rights (IPR). We see an increased potential in this area, and we work with leading patent law firms to capitalize on this opportunity. “Fingerprints has over 700 registered patents in its portfolio, extending from algorithms and biometric image processing through to sensors and hardware packaging technology. A smaller part of this patent portfolio pertains to a field outside...